International Journal of Clinical Oncology

, Volume 16, Issue 2, pp 153–155

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

  • Hideaki Miyake
  • Takahiro Haraguchi
  • Atsushi Takenaka
  • Masato Fujisawa
Case Report

DOI: 10.1007/s10147-010-0116-z

Cite this article as:
Miyake, H., Haraguchi, T., Takenaka, A. et al. Int J Clin Oncol (2011) 16: 153. doi:10.1007/s10147-010-0116-z

Abstract

Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.

Keywords

Collecting duct carcinomaSunitinibMetastasis

Copyright information

© Japan Society of Clinical Oncology 2010

Authors and Affiliations

  • Hideaki Miyake
    • 1
  • Takahiro Haraguchi
    • 1
  • Atsushi Takenaka
    • 1
  • Masato Fujisawa
    • 1
  1. 1.Division of UrologyKobe University Graduate School of MedicineKobeJapan